Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eczema drug nemolizumab put to the vaccine test

NCT ID NCT04365387

Disease control Sponsor: Galderma R&D Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether nemolizumab, a drug for moderate-to-severe eczema, interferes with the body's ability to respond to tetanus and meningococcal vaccines. 242 adults and teens with eczema received either nemolizumab or a placebo, plus the vaccines. The goal was to see if the drug dampens the immune response, which could affect how well vaccines protect them.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nemolizumab
What this could lead to
If successful, this could show that nemolizumab does not weaken vaccine responses, allowing people with eczema to get vaccinated while on treatment.
What could go wrong
This is a small, early-phase study (Phase 2) focused on immune response to vaccines, not on treating eczema itself. Results may not apply to all patients or other vaccines.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

242 people

The number who actually took part.

Started

Mar 2020

Finished

Jul 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 54 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Chronic AD for at least 2 years * EASI score \>= 16 * IGA score \>= 3 * AD involvement \>= 10% of BSA * Peak (maximum) pruritus NRS score of at least 4.0 Exclusion Criteria: * Body weight \< 30 kilogram (kg) * History of hypersensitivity (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody) or to any of the study drug excipients * History of severe allergic reaction to either vaccine or to vaccine components including alum, thimerosal, phenol * Participants for whom administration of the meningococcal vaccine provided in this study is contraindicated or medically inadvisable * Participants for whom administration of the tetanus, diphtheria, and pertussis vaccine provided in this study is contraindicated or medically inadvisable * Receipt of any vaccine (except inactivated influenza vaccine) within 12 weeks prior to screening, any meningococcal vaccine within 1 year prior to screening, or any tetanus-, diphtheria-, or pertussis-containing vaccine within 5 years prior to screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dermatitis, atopic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema Pruritus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dermatitis, atopic

Contacts and locations

Locations

  • Galderma Investigational Site (SIte#8870)

    Boca Raton, Florida, 33433, United States

  • Galderma Investigational Site (Site#8003)

    Webster, Texas, 77598, United States

  • Galderma Investigational Site (Site#8033)

    Clinton Township, Michigan, 48038-1137, United States

  • Galderma Investigational Site (Site#8129)

    Fort Gratiot, Michigan, 48059, United States

  • Galderma Investigational Site (Site#8130)

    Los Angeles, California, 90045, United States

  • Galderma Investigational Site (Site#8142)

    Indianapolis, Indiana, 46250, United States

  • Galderma Investigational Site (Site#8200)

    Goodlettsville, Tennessee, 37072, United States

  • Galderma Investigational Site (Site#8213)

    Ormond Beach, Florida, 32174, United States

  • Galderma Investigational Site (Site#8245)

    Dallas, Texas, 75231, United States

  • Galderma Investigational Site (Site#8329)

    San Antonio, Texas, 78229-3409, United States

  • Galderma Investigational Site (Site#8353)

    Yardley, Pennsylvania, 19067, United States

  • Galderma Investigational Site (Site#8391)

    Hialeah, Florida, 33013, United States

  • Galderma Investigational Site (Site#8420)

    Portsmouth, New Hampshire, 03801, United States

  • Galderma Investigational Site (Site#8428)

    Philadelphia, Pennsylvania, 19104, United States

  • Galderma Investigational Site (Site#8447)

    Fort Smith, Arkansas, 72916, United States

  • Galderma Investigational Site (Site#8532)

    Overland Park, Kansas, 66215, United States

  • Galderma Investigational Site (Site#8578)

    Cerritos, California, 90703, United States

  • Galderma Investigational Site (Site#8739)

    Normal, Illinois, 61761, United States

  • Galderma Investigational Site (Site#8764)

    Tampa, Florida, 33613, United States

  • Galderma Investigational Site (Site#8777)

    Charleston, South Carolina, 29407, United States

  • Galderma Investigational Site (Site#8786)

    Clearwater, Florida, 33765, United States

  • Galderma Investigational Site (Site#8787)

    Plano, Texas, 75093, United States

  • Galderma Investigational Site (Site#8788)

    Orlando, Florida, 32801, United States

  • Galderma Investigational Site (Site#8791)

    Fresno, California, 93720, United States

  • Galderma Investigational Site (Site#8792)

    Doral, Florida, 33122, United States

  • Galderma Investigational Site (Site#8793)

    Towson, Maryland, 21204, United States

  • Galderma Investigational Site (Site#8795)

    Shelby, North Carolina, 28150, United States

  • Galderma Investigational Site (Site#8812)

    Metairie, Louisiana, 70005, United States

  • Galderma Investigational Site (Site#8813)

    Los Angeles, California, 90057, United States

  • Galderma Investigational Site (Site#8817)

    Katy, Texas, 77494, United States

  • Galderma Investigational Site (Site#8828)

    Kew Gardens, New York, 11415, United States

  • Galderma Investigational Site (Site#8831)

    Anaheim, California, 92801, United States

  • Galderma Investigational Site (Site#8833)

    Inglewood, California, 90301, United States

  • Galderma Investigational Site (Site#8836)

    Jacksonville, Florida, 32256, United States

  • Galderma Investigational Site (Site#8837)

    Pomona, California, 91767, United States

  • Galderma Investigational Site (Site#8839)

    Tampa, Florida, 33615, United States

  • Galderma Investigational Site (Site#8840)

    Ocoee, Florida, 34761, United States

  • Galderma Investigational Site (Site#8841)

    Medford, Oregon, 97504, United States

  • Galderma Investigational Site (Site#8843)

    Sweetwater, Florida, 33172, United States

  • Galderma Investigational Site (Site#8844)

    Orem, Utah, 84058, United States

  • Galderma Investigational Site (Site#8845)

    Huntington Beach, California, 92647, United States

  • Galderma Investigational Site (Site#8846)

    Austin, Texas, 78742, United States

  • Galderma Investigational Site (Site#8847)

    Las Vegas, Nevada, 89118, United States

  • Galderma Investigational Site (Site#8848)

    Las Vegas, Nevada, 89144, United States

  • Galderma Investigational Site (Site#8849)

    Troy, Michigan, 48084, United States

  • Galderma Investigational Site (Site#8850)

    Margate, Florida, 33063, United States

  • Galderma Investigational Site (Site#8851)

    Miami, Florida, 33135, United States

  • Galderma Investigational Site (Site#8854)

    Canoga Park, California, 91303, United States

  • Galderma Investigational Site (Site#8855)

    Beaumont, Texas, 77702, United States

  • Galderma Investigational Site (Site#8856)

    Ormond Beach, Florida, 32174, United States

  • Galderma Investigational Site (Site#8856)

    Ormond Beach, Florida, 33174, United States

  • Galderma Investigational Site (Site#8857)

    Oklahoma City, Oklahoma, 73118, United States

  • Galderma Investigational Site (Site#8858)

    Long Beach, California, 90806, United States

  • Galderma Investigational Site (Site#8868)

    Houston, Texas, 77004, United States

  • Galderma Investigational Site (Site#8873)

    Scottsdale, Arizona, 85260, United States

  • Galderma Investigational Site (Site#8876)

    Bridgeton, Missouri, 63044, United States

  • Galderma Investigational Site (Site#9919)

    Raleigh, North Carolina, 27617, United States

  • Galderma Investigational Site (Site#9921)

    Miami Lakes, Florida, 33014, United States

  • Galderma Investigational Site (Site#9922)

    Phoenix, Arizona, 85018, United States

  • Galderma Investigational Site (Site#9924)

    Raritan, New Jersey, 08869, United States

  • Galderma Investigational Site (Site#9935)

    Springville, Utah, 84663, United States

  • Galderma Investigational Site 2 (Site#8816)

    Tampa, Florida, 33613, United States

  • Galderma Investigational Site 2 (Site#8833)

    Inglewood, California, 90301, United States

  • Galderma Investigational Site 2 (Site#8864)

    Las Vegas, Nevada, 89144, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.